Sienna Biopharmaceuticals
Topical dermatology formulations for atopic dermatitis and inflammatory skin conditions
- Sector
- Biotech
- Headquarters
- Weslake Village, CA
- Latest Form D
- $40.5M, May 2017
- Total capital
- $58.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $58.9M
- 2 Form D · last May 2017
- 113 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 12
- 28 pending · first 2016
- Rank in peer group#141 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$40.5M
- Private capital raisedForm D · SEC · 1st filing$18.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#141 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Bob R. MoreDirectorNamed in SEC Form D filings
- Dennis R. FentonDirectorNamed in SEC Form D filings
- Diane F. StroehmannExecutive OfficerNamed in SEC Form D filings
- Frederick C. Beddingfield IIIExecutive Officer, DirectorNamed in SEC Form D filings
- Keith R. Leonard Jr.DirectorNamed in SEC Form D filings
- Kristina R. BurowDirectorNamed in SEC Form D filings
Show all 11 people
- Paul F. LizzulExecutive OfficerNamed in SEC Form D filings
- Ric C. PetersonExecutive OfficerNamed in SEC Form D filings
- Robert R. NelsenDirectorNamed in SEC Form D filings
- Timothy K. AndrewsExecutive OfficerNamed in SEC Form D filings
- Todd C. HarrisExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 12 granted of 40- GrantedUltrasound Delivery Of NanoparticlesUSPTOUS 10,537,640
- PendingFormulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureUSPTOApplication 16208278
- PendingEnhanced Efficacy And Targeted Topical Delivery Of Drugs To Skin With NanoparticlesUSPTOApplication 15559397
Show all 40 patent records
- Ultrasound Delivery Of NanoparticlesJan 21, 2020 · US 10,537,640Granted
- Formulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureJul 11, 2019 · Application 16208278Pending
- Enhanced Efficacy And Targeted Topical Delivery Of Drugs To Skin With NanoparticlesMar 15, 2018 · Application 15559397Pending
- Ultrasound Delivery Of NanoparticlesFeb 21, 2017 · US 9,572,880Granted
- Thermal Treatment Of Acne With Coated Metal NanoparticlesSep 20, 2016 · US 9,446,126Granted
- Thermal Treatment Of The Skin Surface With Metal Nanoparticles In Surfactant Containing SolutionsSep 13, 2016 · US 9,439,965Granted
- Thermal Treatment Of The Skin Surface With Coated Metal NanoparticlesSep 13, 2016 · US 9,439,964Granted
- Thermal Treatment Of Acne With Metal Nanoparticles In Surfactant Containing SolutionsSep 6, 2016 · US 9,433,678Granted
- Hair Removal With Nanoparticles With Coatings That Facilitate Selective Removal From The Skin SurfaceSep 6, 2016 · US 9,433,676Granted
- Thermal Treatment Of A Pilosebaceous Unit With Metal Nanoparticles In Surfactant Containing SolutionsSep 6, 2016 · US 9,433,677Granted
- Hair Removal With Metal Nanoparticles In Surfactant Containing SolutionsAug 30, 2016 · US 9,427,467Granted
- Thermal Treatment Of Acne With Nanoparticles With Coatings That Facilitate Selective Removal From The Skin SurfaceAug 23, 2016 · US 9,421,260Granted
- Hair Removal With Coated Metal NanoparticlesAug 23, 2016 · US 9,421,259Granted
- Thermal Treatment Of The Skin Surface With Nanoparticles With Coatings That Facilitate Selective Removal From The Skin SurfaceAug 23, 2016 · US 9,421,261Granted
- Use Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62702273Pending
- Polymer Conjugates Of Staurosporine Derivatives Having Reduced ExposureApplication 62702285Pending
- Polymer Conjugates Of Staurosporine Derivatives Having Reduced ExposureApplication PCTUS2018023133Pending
- Polymer Conjugates Targeting C-src With Reduced ExposureApplication PCTUS2018023109Pending
- Uses Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication PCTUS2018023102Pending
- Reduced Exposure Compositions Modulating Therapeutic TargetsApplication PCTUS2018023174Pending
- Polymer Conjugate Of Montesanib With Reduced ExposureApplication PCTUS2018023108Pending
- Polymer Conjugates Targeting Mediators Of Gastrointestinal Disorders With Reduced ExposureApplication 62634691Pending
- Formulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62632676Pending
- Formulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62619019Pending
- Formulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62608366Pending
- Formulations For Dermal Delivery Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62594428Pending
- Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62590111Pending
- Polymer Conjugates Targeting Vascular Endothelial Growth Factor Receptors With Reduced ExposureApplication 62590119Pending
- Polymer Conjugates Targeting C-src With Reduced ExposureApplication 62590131Pending
- Polymer Conjugates Targeting Mediators Of Inflammatory Bowel Diseases And Other Conditions With Reduced ExposureApplication 62590148Pending
- Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 62504111Pending
- Reduced Exposure Compositions Modulating Therapeutic TargetsApplication PCTUS2019042825Pending
- Polymer Conjugates Targeting Vascular Endothelial Growth Factor Receptors With Reduced ExposureApplication 62501568Pending
- Polymer Conjugates Targeting Mediators Of Inflammatory Bowel Diseases And Other Conditions With Reduced ExposureApplication 62501651Pending
- Polymer Conjugates Targeting C-src With Reduced ExposureApplication 62473972Pending
- Polymer Conjugates Targeting Vascular Endothelial Growth Factor Receptors With Reduced ExposureApplication 62473982Pending
- Polymer Conjugates Targeting Mediators Of Inflammatory Bowel Diseases And Other Conditions With Reduced ExposureApplication 62473975Pending
- Enhanced Efficacy And Targeted Topical Delivery Of Drugs To Skin With NanoparticlesApplication PCTUS2016023174Pending
- Uses Of Polymer Conjugates Of Indolocarbazole Compounds With Reduced ExposureApplication 16612029Pending
- Reduced Exposure Conjugates Modulating Therapeutic TargetsApplication 16495811Pending
Related companies, and why
- Cerberus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Mi-Helper, Inc.Similar federal contract value in Biotech · null in contracts
- Revere Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- Vima TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Lyndra Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Triveni BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .